TVTX insider trading — Travere Therapeutics, Inc.
Over the last 90 days, insiders at Travere Therapeutics, Inc. (TVTX) made 0 open-market purchases worth $0 and 1 open-market sale worth $43K, making them net sellers by $43K. The largest sale was by Cline Christopher R. (CHIEF FINANCIAL OFFICER), who sold 642 shares for $43K on Sep 2, 2026.
Updated Oct 16, 2026.
Recent TVTX insider transactions
Every Form 4 filed by Travere Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 8,282 | $22.40 | $186K | Form 4 |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | S · Sale · 10b5-1 | Direct | 8,282 | $65.07 | $539K | Form 4 |
| Sep 16, 2026 | Rote William E. | Chief Research Officer | M · Option exercise · 10b5-1 | Direct | 112,850 | $21.29 | $2.40M | Form 4 |
| Sep 16, 2026 | Rote William E. | Chief Research Officer | S · Sale · 10b5-1 | Direct | 112,850 | $63.33 | $7.15M | Form 4 |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 172,717 | $14.19 | $2.45M | Form 4 |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | S · Sale · 10b5-1 | Direct | 172,717 | $63.43 | $10.96M | Form 4 |
| Sep 15, 2026 | Rote William E. | Chief Research Officer | M · Option exercise · 10b5-1 | Direct | 78,650 | $21.57 | $1.70M | Form 4 |
| Sep 15, 2026 | Rote William E. | Chief Research Officer | S · Sale · 10b5-1 | Direct | 96,198 | $62.25 | $5.99M | Form 4 |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 77,190 | $18.31 | $1.41M | Form 4 |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | S · Sale · 10b5-1 | Direct | 102,190 | $62.26 | $6.36M | Form 4 |
| Sep 15, 2026 | Inrig Jula | EVP, Head of R&D & CMO | M · Option exercise · 10b5-1 | Direct | 32,395 | $8.93 | $289K | Form 4 |
| Sep 15, 2026 | Inrig Jula | EVP, Head of R&D & CMO | S · Sale · 10b5-1 | Direct | 44,674 | $62.34 | $2.79M | Form 4 |
| Sep 15, 2026 | Reed Elizabeth E | Chief Legal Officer and GC | M · Option exercise · 10b5-1 | Direct | 37,500 | $15.46 | $580K | Form 4 |
| Sep 15, 2026 | Reed Elizabeth E | Chief Legal Officer and GC | S · Sale · 10b5-1 | Direct | 37,500 | $62.34 | $2.34M | Form 4 |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | M · Option exercise · 10b5-1 | Direct | 108,493 | $23.34 | $2.53M | Form 4 |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | S · Sale · 10b5-1 | Direct | 108,493 | $64.61 | $7.01M | Form 4 |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | M · Option exercise · 10b5-1 | Direct | 195,841 | $23.34 | $4.57M | Form 4 |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | S · Sale · 10b5-1 | Direct | 195,841 | $63.45 | $12.43M | Form 4 |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | M · Option exercise · 10b5-1 | Direct | 95,666 | $23.34 | $2.23M | Form 4 |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | S · Sale · 10b5-1 | Direct | 95,666 | $62.26 | $5.96M | Form 4 |
| Sep 15, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 20,000 | $17.44 | $349K | Form 4 |
| Sep 15, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S · Sale · 10b5-1 | Direct | 50,508 | $62.34 | $3.15M | Form 4 |
| Sep 15, 2026 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M · Option exercise · 10b5-1 | Direct | 5,375 | $24.19 | $130K | Form 4 |
| Sep 15, 2026 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S · Sale · 10b5-1 | Direct | 5,375 | $62.33 | $335K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey A | Director | M · Option exercise · 10b5-1 | Direct | 20,000 | $21.98 | $440K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey A | Director | S · Sale · 10b5-1 | Direct | 20,000 | $67.31 | $1.35M | Form 4 |
| Sep 2, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S · Sale | Direct | 642 | $66.37 | $43K | Form 4 |
| Aug 18, 2026 | Lyons Gary A | Director | M · Option exercise · 10b5-1 | Direct | 5,000 | $17.44 | $87K | Form 4 |
| Aug 18, 2026 | Lyons Gary A | Director | S · Sale · 10b5-1 | Direct | 5,000 | $63.37 | $317K | Form 4 |
| Aug 17, 2026 | Lyons Gary A | Director | M · Option exercise · 10b5-1 | Direct | 5,000 | $17.44 | $87K | Form 4 |
| Aug 17, 2026 | Lyons Gary A | Director | S · Sale · 10b5-1 | Direct | 5,000 | $63.20 | $316K | Form 4 |
TVTX insider trading FAQ
Are insiders buying TVTX stock?
Not on the open market. In the last 90 days, Travere Therapeutics, Inc. insiders made no open-market purchases, and 1 open-market sale totaling $43K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading TVTX?
Recent sellers: Cline Christopher R..
Where does TVTX insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.